Wilms tumor (WT)1 gene expression in children with acute leukemia in Serbia
Open Access
- 1 January 2016
- journal article
- Published by National Library of Serbia in Genetika
- Vol. 48 (1) , 409-421
Abstract
Acute leukemias constitute the most common malignancy in childhood, accounting for 25-35% of all cancer in children. They are divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Genetic susceptibility is known to play a major role in childhood leukemias. Wilms tumor (WT)1 is a zinc finger transcription factor involved in regulating the process of cell differentiation; it has been implicated in a wide range of human neoplasms. WT1 overexpression in the bone marrow at diagnosis is reported to be an independent negative prognostic factor in adults and children with AML. The aim of the present investigation was to determine the expression of WT1 in the bone marrow of children with AML and ALL in Serbia and its possible impact on patient survival. We determined bone marrow WT1 expression levels by reverse-transcription polymerase chain reaction (RT-PCR) at diagnosis in 20 children with AML and 20 children with ALL (16 B-ALL and 4 T-ALL), as well as 15 age- and sex-matched controls who were evaluated for immune thrombocytopenic purpura (ITP). For children with AML, follow-up samples were also analyzed one month after treatment initiation and at variable later timepoints of control punctures. The results were normalized based on WT1 expression in controls. We found that children with AML had significantly higher WT1 expression at diagnosis (median ? SD: 139.42 ? 244.03) than those with ALL (1.18 ? 54.37; Mann-Whitney U=82; p<0.01) and ITP (0.76 ? 1.01; U=32; p<0.01). Patients with T-ALL had higher WT1 expression than those with B-ALL, though significance was not reached due to subgroup size; differences between AML subgroups according to the French-American-British (FAB) classification were also below the level of significance, though a tendency toward higher values in M3 and M4 leukemias was notable. There was also a tendency toward higher values in 14 children with AML who were still alive after a median follow-up of 1.5 years (181.42 ? 192.52) than in 6 who succumbed to the disease (104.29 ? 354.87). All children with AML who had WT1 expression 1 month after diagnosis below the fourth quartile (10 of 10) were still alive, while only 2 of 5 with 1-month WT1 expression in the fourth quartile survived (Fisher?s exact test: p=0.0952). Taken together, our results support a role for WT1 in the diagnostic workup in children with acute leukemia, although it needs to be considered in view of a complex and indvidualized context. [Projekat Ministarstva nauke Republike Srbije, br. 41004] This article has been corrected. Link to the correction 10.2298/GENRSR1602799EKeywords
This publication has 25 references indexed in Scilit:
- WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic FactorsPathology and Oncology Research, 2015
- Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicineBlood, 2015
- Childhood Cancer for the Primary Care PhysicianPrimary Care: Clinics in Office Practice, 2015
- Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseasesJournal of Cancer Research and Clinical Oncology, 2014
- Molecular genetics of B-precursor acute lymphoblastic leukemiaJournal of Clinical Investigation, 2012
- WT1 expression at diagnosis does not predict survival in pediatric aml: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2009
- The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesisExpert Reviews in Molecular Medicine, 2007
- High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid LeukemiaJournal of Clinical Oncology, 2006
- Clinical Significance of Minimal Residual Disease in Childhood Acute Myeloid LeukemiaInternational Journal of Hematology, 2004
- Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical ApplicationInternational Journal of Hematology, 2001